Drug Type Live attenuated vaccine, Prophylactic vaccine |
Synonyms modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus, modified vaccinia Ankara virus, Modified Vaccinia Ankara-Bavarian Nordic + [11] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
RegulationEmergency Use Authorization (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Smallpox vaccine(Bavarian Nordic A/S) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Monkeypox | EU | 31 Jul 2013 | |
Monkeypox | IS | 31 Jul 2013 | |
Monkeypox | LI | 31 Jul 2013 | |
Monkeypox | NO | 31 Jul 2013 | |
Smallpox | EU | 31 Jul 2013 | |
Smallpox | IS | 31 Jul 2013 | |
Smallpox | LI | 31 Jul 2013 | |
Smallpox | NO | 31 Jul 2013 | |
Vaccinia | EU | 31 Jul 2013 | |
Vaccinia | IS | 31 Jul 2013 | |
Vaccinia | LI | 31 Jul 2013 | |
Vaccinia | NO | 31 Jul 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pregnancy | Phase 3 | CG | 31 Mar 2025 | |
Dermatitis, Atopic | Phase 2 | US | 01 Jul 2006 | |
Dermatitis, Atopic | Phase 2 | MX | 01 Jul 2006 | |
HIV Infections | Phase 2 | US | 01 Jun 2006 | |
HIV Infections | Phase 2 | PR | 01 Jun 2006 | |
Rhinitis, Allergic, Seasonal | Phase 1 | DE | 01 Apr 2004 |
NCT05512949 (NEWS) Manual | Phase 2 | 229 | (aged between 12 and 17 years) | zukosueccw(qzcshixkoi) = After two doses, antibody levels were found to be equivalent at day 43 to those in adults aged 18 to 50 years. bfldcmuhdg (qhjiwyunbj ) View more | Positive | 17 Oct 2024 | |
Literature Manual | Not Applicable | 45 | MVA-BN 2 doses | jbthqrldlz(uarlfmwsiq) = 2 doses: mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 112, 384, 85, 29, and 76 at week 3 after vaccination but then declined to 38, 82, 32, 25, and 31 at 12 months; 1 dose: the median binding antibody ELISA titers to mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 45, 90, 32, 31, and 28 at week 3 but then declined to 33, 43, 30, 25, and 28 at 12 months tmohnbqyyg (aoypjtbtcf ) | Negative | 03 Oct 2024 | |
MVA-BN 1 doses | |||||||
NCT05740982 (NEWS) Manual | Phase 2 | 526 | (adolescents 12-17 years of age) | gemzvsyalg(udcxqxzkqm) = a similar safety profile between both age groups hlcmnihall (ccxoytmhjl ) View more | Positive | 19 Sep 2024 | |
IMVANEX (adults aged 18 years and older) | |||||||
Phase 2 | 229 | MVA-BN (2 x 10^7 ID MVA-BN) | xzwuolbnhx(rfkwrrkzcn) = mbnyamfuml pwvgneaqxt (tycryahflq, oofddyxmgr - szduznfdiu) View more | - | 09 Jan 2024 | ||
MVA-BN (1 x 10^7 ID MVA-BN) | xzwuolbnhx(rfkwrrkzcn) = cvilegxzft pwvgneaqxt (tycryahflq, dznoxyulso - wnmoyxksdz) View more | ||||||
NCT03699124 (Pubmed) Manual | Phase 3 | - | 1,129 | ppsypquyun(mwilagcbna) = jzvmrebclg ucqspbiohm (ltsjwkzwbb ) View more | Positive | 29 Nov 2022 | |
Phase 3 | 1,129 | (GP 1: Two Doses of FD MVA-BN--Lot 1) | geeaqewwjh(yunddhdvbh) = ccleqbtkkh klqirlsufs (sggognfkwh, hhnleykmgn - ndxhbsuvgc) View more | - | 27 May 2021 | ||
(GP 2: Two Doses of FD MVA-BN--Lot 2) | geeaqewwjh(yunddhdvbh) = qqdhhnizer klqirlsufs (sggognfkwh, jswxdnpahz - oarbddmqiv) View more | ||||||
Phase 2 | 651 | LF (LF Formulation) | ufzfkpezjk(nwfaktuogb) = bclibbvnkk rhsoykxzil (chreognxwu, ftqrsavvfl - rjyeykozjc) View more | - | 12 Oct 2020 | ||
(FD Formulation) | ufzfkpezjk(nwfaktuogb) = ghnivjcbpv rhsoykxzil (chreognxwu, brinylkdvj - ylpyucdxlv) View more | ||||||
Phase 4 | - | 22 | cnpkwgwlwm(gxcnmmwthj) = zxcdnhtglk wpivayokdh (xhmyfdjfeh, erdzszighk - mdqbxmgdfg) View more | - | 19 Aug 2020 | ||
Phase 3 | 433 | zxbfoprsaj(sklzeyosuw): RO = 97.9 (95% CI, 96.6 - 98.3) View more | Superior | 14 Nov 2019 | |||
Phase 2 | 304 | (Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose) | byypfcojgd(wfgxrbftfn) = mhdfsmadcw umginzlowg (duxispficf, octeyoihol - lfvqufcyqw) View more | - | 18 Feb 2019 | ||
(Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose) | byypfcojgd(wfgxrbftfn) = sqktkgxwnh umginzlowg (duxispficf, qmtiyctdfo - npfzsgblrw) View more |